The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)-Reference-Cited by-同舟云学术

The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691)

Published:2011-03-30 Issue:6 Volume:89 Page:821-829
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Fidock M D,Souberbielle B E,Laxton C,Rawal J,Delpuech-Adams O,Corey T P,Colman P,Kumar V,Cheng J B,Wright K,Srinivasan S,Rana K,Craig C,Horscroft N,Perros M,Westby M,Webster R,van der Ryst E

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference33 articles.

1. The global burden of hepatitis C

2. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

3. Side effects of therapy of hepatitis C and their management

4. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

5. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants;Journal of Medicinal Chemistry;2024-05-24

2. The role of Toll‐like receptors in neuropsychiatric disorders: Immunopathology, treatment, and management;Medicinal Research Reviews;2024-01-16

3. Combination Therapy with a TLR7 Agonist and a BRD4 Inhibitor Suppresses Tumor Growth via Enhanced Immunomodulation;International Journal of Molecular Sciences;2024-01-04

4. Design, synthesis and biological evaluation of quinazoline and pyrrolo[3,2-d]pyrimidine derivatives as TLR7 agonists for antiviral agents;Organic & Biomolecular Chemistry;2024

5. Toll-Like Receptors 7/8: A Paradigm for the Manipulation of Immunologic Reactions for Immunotherapy;Viral Immunology;2023-11-01